The combined data from ReAct and ReAlise include more than 6,600 RA patients and provide one of the largest well-monitored evaluations of the long-term safety and effectiveness of a single TNF antagonist in routine clinical practice settings. The gene discussed is TNF; the disease is rheumatoid arthritis.